GEN Exclusives

More »

GEN News Highlights

More »
Jul 30, 2012

ClinTec Sets Up Shop in Malawi

  • ClinTec International has expanded its operations into Malawi, increasing its presence in the markets of Africa, Asia, and the Middle East. The company is in the process of recruiting personnel with vaccine research experience to join its teams in Africa and Asia. Africa is a pivotal region for the development of adult and pediatric vaccines against infectious diseases.

    “I am pleased with our continued expansion in Africa and see huge potential for the company in conducting large scale vaccine trials,” said Rabinder Buttar, Ph.D. “Despite the challenging economic conditions through which many of our clients are restructuring their organizations, ClinTec continues to grow and win major new business from pharma companies. The company is continuing to expand into interesting new regions for clinical research. As the pharmaceutical industry increasingly focuses its drug development efforts on the emerging markets, ClinTec will closely partner with its clients, aligning its services and operations to fit with their needs.”

    ClinTec International is a CRO with a presence in over 40 developed and emerging countries, covering Western Europe, Central and Eastern Europe, the Middle East and Africa, Central and South Africa, Latin America, Asia, and the U.S.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?